2月13日—15日,美国临床肿瘤学会泌尿生殖系统肿瘤研讨会(ASCO GU)在美国旧金山召开。ASCO GU是单独针对泌尿生殖系统肿瘤的国际大会,每年来自世界各地的顶级医学专家都希望在这场学术盛会上分享自己的最新成果。 今年大会上,辉瑞最受关注的研究之一是TALAPRO-2Ⅲ期临床试验关键结果。结果显示,无论患者是否存在HRR基因突变,他拉唑帕利与恩扎卢胺的联合用药均能显著延长转移性去势抵抗性...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.